CN117263898A - 一种玻色因及其生产方法和用途 - Google Patents
一种玻色因及其生产方法和用途 Download PDFInfo
- Publication number
- CN117263898A CN117263898A CN202211491049.2A CN202211491049A CN117263898A CN 117263898 A CN117263898 A CN 117263898A CN 202211491049 A CN202211491049 A CN 202211491049A CN 117263898 A CN117263898 A CN 117263898A
- Authority
- CN
- China
- Prior art keywords
- xylopyranoside
- beta
- hydroxypropane
- catalyst
- vitreous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 239000011521 glass Substances 0.000 title abstract description 18
- KOGFZZYPPGQZFZ-QVAPDBTGSA-N (2s,3r,4s,5r)-2-(2-hydroxypropyl)oxane-3,4,5-triol Chemical compound CC(O)C[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O KOGFZZYPPGQZFZ-QVAPDBTGSA-N 0.000 claims abstract description 27
- 239000002537 cosmetic Substances 0.000 claims abstract description 14
- 230000000975 bioactive effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 22
- 239000003054 catalyst Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 8
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 8
- 108010031318 Vitronectin Proteins 0.000 claims description 7
- 102100035140 Vitronectin Human genes 0.000 claims description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 2
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 claims description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 2
- HCGFUIQPSOCUHI-UHFFFAOYSA-N 2-propan-2-yloxyethanol Chemical compound CC(C)OCCO HCGFUIQPSOCUHI-UHFFFAOYSA-N 0.000 claims description 2
- IBOFVQJTBBUKMU-UHFFFAOYSA-N 4,4'-methylene-bis-(2-chloroaniline) Chemical compound C1=C(Cl)C(N)=CC=C1CC1=CC=C(N)C(Cl)=C1 IBOFVQJTBBUKMU-UHFFFAOYSA-N 0.000 claims description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 2
- 150000004985 diamines Chemical class 0.000 claims description 2
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical group PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 claims description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000005984 hydrogenation reaction Methods 0.000 description 8
- 239000003513 alkali Substances 0.000 description 6
- 239000007810 chemical reaction solvent Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000004266 Collagen Type IV Human genes 0.000 description 3
- 108010042086 Collagen Type IV Proteins 0.000 description 3
- 102000004510 Collagen Type VII Human genes 0.000 description 3
- 108010017377 Collagen Type VII Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229930007927 cymene Natural products 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 229930182476 C-glycoside Natural products 0.000 description 2
- 150000000700 C-glycosides Chemical class 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WDYGPMAMBXJESZ-SFHVURJKSA-N (2s)-1,1-bis(4-methoxyphenyl)-3-methylbutane-1,2-diamine Chemical compound C1=CC(OC)=CC=C1C(N)([C@@H](N)C(C)C)C1=CC=C(OC)C=C1 WDYGPMAMBXJESZ-SFHVURJKSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000221095 Simmondsia Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IRTLGLYSFAKASM-UHFFFAOYSA-N acetic acid;propan-2-ol Chemical compound CC(C)O.CC(O)=O IRTLGLYSFAKASM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- -1 polydimethylsiloxane Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 150000003741 xylose derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
Abstract
发明提供一种玻色因及其生产方法和在化妆品中用途,所述玻色因中C‑β‑D‑吡喃木糖苷‑2‑羟基丙烷含量95%以上,并含有C‑β‑D‑吡喃木糖苷‑2‑(S)‑羟基丙烷和C‑β‑D‑吡喃木糖苷‑2‑(R)‑羟基丙烷,其中C‑β‑D‑吡喃木糖苷‑2‑(S)‑羟基丙烷过量且de值92%以上。与现有的玻色因产品相比,本发明的玻色因产品的生物活性异构体更加过量,提高产品生物活性。
Description
技术领域
本发明提供一种玻色因产品及其生产方法和在化妆品中用途。属于制药及化学领域。
背景技术
玻色因(Pro-Xylane),英文INCI(国际化妆品命名)名称为“Hydroxypropyltetrahydropyrantriol”,即羟丙基四氢吡喃三醇,化学结构为C-β-D-吡喃木糖苷-2-羟基丙烷(式I),是一种具有抗衰老活性的木糖衍生物,可以促进胶原蛋白的合成,使肌肤更强韧有弹性,改善颈部细纹,预防衰老,WO 02051828公开了其化学结构、制备和在化妆品中应用。
羟丙基四氢吡喃三醇的立体化学特征对玻色因生物活性具有重要影响,β-糖苷键对维持羟丙基四氢吡喃三醇的生物活性是不可缺少的。化学合成的玻色因,羟丙基四氢吡喃三醇的糖苷键都是β-型的,即均为C-β-D-吡喃木糖苷-2-羟基丙烷。同时,由于糖苷配基(即羟基丙烷侧链)中羟基(2-位手性碳上)的立体构型不同,存在2-(S)和2-(R)两种非对映异构体,即C-β-D-吡喃木糖苷-2-(S)-羟基丙烷和C-β-D-吡喃木糖苷-2-(R)-羟基丙烷,在化妆品目录中玻色因是2-(R)立体异构体与2-(S)立体异构体的混合物。CN1699390A公开了C-β-D-吡喃木糖苷-2-羟基丙烷的2-(S)异构体及其制备和化妆品中用途,并公开了2-(S)异构体优于2-(R)异构体。
CN1699390A经还原反应制得C-β-D-吡喃木糖苷-2-羟基丙烷产物,经硅胶色谱纯化获得2-(S)异构体即C-β-D-吡喃木糖苷-2-(S)-羟基丙烷,没有公开反应的立体选择性以及产物光学纯度。Cavezza A.等,Synthesis of Pro-XylaneTM:A new biologicallyactive C-glycoside in aqueous media,Bioorganic&Medicinal Chemistry Letters,2009,19(3):845-849,公开了玻色因原料即羟丙基四氢吡喃三醇的化学合成工艺,在水中用硼氢化钠还原C-β-D-吡喃木糖苷-2-丙酮可以得到2-(S)/2-(R)比例接近1:1的产物,而在异丙醇-醋酸混合物中用硼氢化钠还原C-β-D-吡喃木糖苷-2-丙酮可以选择性得到2-(S)构型的立体异构体,de值为90%,用NaBH(OAc)3还原C-β-D-吡喃木糖苷-2-丙酮可以选择性得到2-(S)构型的立体异构体,de值为92%。
de值表示非对映体过量值(diastereomeric exce ss),描述非对映异构体混合物组成,是一个非对映异构体对另一个非对映异构体的过量值,计算公式如下:
D1和D2分别代表两个非对映异构体所占产物的摩尔分数。
现有技术研究表明了C-β-D-吡喃木糖苷-2-(S)-羟基丙烷在羟丙基四氢吡喃三醇2-(S)/2-(R)异构体混合物中的比例对生物活性具有重要影响,但是现有技术提供的羟丙基四氢吡喃三醇及其生产工艺中,2-(S)异构体的立体选择性不高,de值最高为92%,进一步分离或纯化以提高羟丙基四氢吡喃三醇中2-(S)异构体比例,难度大而且生产成本高,因此现有技术的玻色因产品中仍存在较大比例的2-(R)异构体,影响了产品的生物活性。因此,提供具有高的2-(S)异构体含量的玻色因原料,是亟待解决的问题之一。
发明内容
本发明所要解决的技术问题是提供一种2-(S)异构体含量高的玻色因原料,具体地说,提供一种玻色因原料,其中2-(S)异构体在2-(S)/2-(R)异构体混合物中的比例高,de值超过92%。本发明还提供所述的玻色因原料制备方法以及在化妆品中的用途。
本发明技术方案如下:
发明提供一种玻色因,其特征是所述玻色因中C-β-D-吡喃木糖苷-2-羟基丙烷含量95%以上,并含有C-β-D-吡喃木糖苷-2-(S)-羟基丙烷和C-β-D-吡喃木糖苷-2-(R)-羟基丙烷,其中C-β-D-吡喃木糖苷-2-(S)-羟基丙烷过量且de值92%以上;优选地,所述的玻色因,其中所述de值92.5%以上;更优选地,所述玻色因,其中所述de值为98.5%以上。
作为优选地,上述所述的玻色因,其中C-β-D-吡喃木糖苷-2-羟基丙烷含量超过95%,接近或等于100%;更优选地,所述的C-β-D-吡喃木糖苷-2-羟基丙烷含量98.5%以上。
更优选地,本发明上述所述的玻色因,其中所述C-β-D-吡喃木糖苷-2-羟基丙烷含量为(98.5-99.5)%,且所述de值为(98.5-99.5)%
作为本发明另一目的,还提供一种制备上述所述的玻色因的方法,其包括C-β-D-吡喃木糖苷-2-丙酮在碱和手性催化剂存在下在溶剂中催化氢化还原生成C-β-D-吡喃木糖苷-2-(S)-羟基丙烷的步骤,其中所述的手性催化剂为双膦双胺钌催化剂。
上述所述的方法,其中所述的催化剂中双膦配体是选自如下配体的S-异构体。
上述所述的方法,其中所述的催化剂中双胺配体是如下配体的S-异构体。
上述所述的方法,其中手性催化剂使用量,例如可以为反应原料摩尔数的(0.05~1.0)mol%。
上述所述的方法,其中所述溶剂,例如可以为甲醇、乙醇、异丙醇、正丙醇、正丁醇、异丁醇、叔丁醇、乙二醇单甲醚、乙二醇单乙醚、乙二醇单丁醚、乙二醇单异丙醚。优选地,所述溶剂为异丙醇。
上述所述的方法,其中所述碱选自碳酸钾、碳酸钠、氢氧化钠、氢氧化钾、氢氧化锂、叔丁醇钾、叔丁醇钠、叔丁醇锂、甲醇钠、乙醇钠。优选地,所述碱为叔丁醇钾。所述方法,其中所述碱的使用量,例如可以为反应原料摩尔数的(0.05~10.0)mol%。
上述所述的方法,其中所用氢气的反应压力为1atm~80atm,优选的,反应压力为30atm~50atm。
上述所述的方法,其中反应温度可以为10℃~100℃,优选的,反应温度为50℃~80℃。
上述所述的方法,其中反应时间,例如可以为3~20小时。
作为本发明另一目的,提供一种组合物,其特征在于含有上述所述玻色因作为生物活性物质和生理学上可接受的辅料。
上述所述的组合物,其中所述玻色因用量,可以按照本领域技术人员所熟知的用量范围,根据实际需要选用合适用量。例如,所述玻色因用量以占组合物总重量的0.00001%-25%重量的量;优选地,所述玻色因用量以占组合物总重量的0.0001%-10%重量的量。
上述所述的组合物,其中所述的辅料为生理学上可接受的辅料,例如为药品或化妆品中可接受的辅料或介质。本领域技术人员可以根据实际需要选用合适的辅料或介质。
作为本发明另一目的,还提供了上述所述的玻色因在制备化妆品中的应用;优选地,所述的化妆品用于抗衰老。例如,保持和/或恢复皮肤的柔软和弹性的化妆品,或者保持和/或刺激皮肤的增加水分的化妆品,或者对抗与透明质酸功能不足相关的皮肤脱水的化妆品等。
本发明提供的玻色因产品,与现有的玻色因产品相比,活性异构体即C-β-D-吡喃木糖苷-2-(S)-羟基丙烷过量且de值超过92%,特别是本发明提供的玻色因,C-β-D-吡喃木糖苷-2-羟基丙烷含量(98.5-99.5)%,且C-β-D-吡喃木糖苷-2-(S)-羟基丙烷过量及de值为(98.5-99.5)%,提高了玻色因产品的生物活性效果。本发明提供所述的玻色因产品的制备方法,高收率、高选择性地生成了C-β-D-吡喃木糖苷-2-(S)-羟基丙烷,避免了高复杂、高成本分离纯化以降低产品中2-(R)异构体比例,而且反应条件温和,收率高,安全可靠,所用溶剂易于除去,适合于工业化生产。
附图说明
图1:实施例1产品1H NMR谱图
图2:实施例1产品13C NMR谱图
图3:不同de值玻色因的Ⅳ型胶原蛋白的相对含量
图4:不同de值玻色因的Ⅶ型胶原蛋白的相对含量
具体实施方式
提供如下具体实施例,仅用于更好解释或理解本发明内容,其不应理解为对本发明保护范围构成限制,本发明的实施方式也不限于以下实施例。
本发明玻色因产品中C-β-D-吡喃木糖苷-2-羟基丙烷含量以及非对映异构体的测定,可以按照现有技术方法进行测定。例如参照CN112697933A公开的方法,测定所制得的玻色因产品中C-β-D-吡喃木糖苷-2-羟基丙烷含量及其非对映异构体比例以及de值。
制备方法
手性催化剂制备:参照文献方法(Ohkuma,T.等,J.Am.Chem.Soc.1995,117,2675-2676)。以实施例1中催化剂为例,将[RuCl2(benzene)]2(5.0mg,0.01mmol)和(S)-Xyl-SunPhos(17.2mg,0.02mmol)加入到20mL的Schlenk管中,氮气置换三次后,再加入新鲜蒸馏且反复冻融脱气的N,N-二甲基甲酰胺(1.5mL)。将此混合物在100℃加热10分钟,得到红棕色溶液。将此溶液冷至室温,加入(S)-Daipen(6.9mg,0.02mmol),然后在25℃搅拌3小时。减压(1Torr)蒸除溶剂,得到棕黄色固体,即为催化剂,可直接用于催化氢化。
玻色因制备:将β-D-吡喃木糖苷-2-丙酮(19.0g,100mmol)加入氢化釜中,加入溶剂180mL,氮气置换三次,加入手性催化剂(0.1mmol),碱(0.5mmol),氢气置换三次,设定合适的氢气压力,加热至合适温度,搅拌反应至反应体系不再吸氢,停止反应。冷却反应釜至室温,缓慢排放氢气。将反应釜中的物料转移到250mL三口瓶中,加入5g硅藻土和1mL 30%双氧水,室温搅拌15min,过滤,滤饼用相应的氢化时采用的溶剂洗涤两次,每次15mL。合并溶液,减压蒸馏除去溶剂,得到类白色固体。加入无水乙醇搅拌溶解,加入适量低极性有机溶剂,降温至-10℃,析出结晶,过滤收集,母液浓缩,所得固体再次用上述方法重结晶,得白色固体,测定含量及非对映异构体纯度(de)。
实施例1
异丙醇为反应溶剂,Ru(benzene)Cl2/S-Xyl-Sunphos/S-Daipen为催化剂,叔丁醇钾为碱,氢化温度60℃,氢化压力50atm,反应10小时,得类白色固体18.9g,收率99.4%。重结晶后得到白色固体。
比旋光度:-38°(20℃于甲醇中,浓度[C]=1g/100mL)。
测定核磁共振谱,如图1、2所示。
1H NMR:(400MHz,D2O)4.04-3.99(m,1H),3.93-3.89(m,1H),3.60-3.53(m,1H),3.39-3.14(m,4H),1.93-1.87(m,1H),1.68-1.60(m,1H),1.18(d,J=6.4Hz,3H)。
13C NMR:(100MHz,D2O)78.4,77.3,73.6,69.4,68.8,65.6,39.9,21.4.
HPLC检测也与对照品一致。
含量及非对映异构体检测。结果:C-β-D-吡喃木糖苷-2-羟基丙烷的含量为99.3%;C-β-D-吡喃木糖苷-2-(S)-羟基丙烷:C-β-D-吡喃木糖苷-2-(R)-羟基丙烷比例为99.65:0.35,de值99.3%。
实施例2
乙醇为反应溶剂,Ru(cymene)Cl2/S-Binap/S-Daipen为催化剂,叔丁醇钾为碱,氢化温度60℃,氢化压力50atm,反应10小时,得类白色固体18.9g,收率99.4%。重结晶后得到白色固体,含量95.5%,de值92.9%。
实施例3
异丙醇为反应溶剂,Ru(cymene)Cl2/S-Binap/S-Daipen为催化剂,碳酸钾为碱,氢化温度60℃,氢化压力50atm,反应10小时,得类白色固体18.8g,收率97.8%。重结晶后得到白色固体,含量96.5%,de值94.9%。
实施例4
异丙醇为反应溶剂,Ru(cymene)Cl2/S-Segphos/S-Daipen为催化剂,叔丁醇钾为碱,氢化温度60℃,氢化压力50atm,反应10小时,得类白色固体18.9g,收率99.4%。重结晶后得到白色固体,含量98.8%,de值98.6%。
实施例5
异丙醇为反应溶剂,Ru(benzene)Cl2/S-Segphos/S-Daipen为催化剂,叔丁醇钾为碱,氢化温度80℃,氢化压力30atm,反应10小时,得类白色固体18.9g,收率99.4%。重结晶后得到白色固体,含量98.9%,de值98.6%。
实施例6
异丙醇为反应溶剂,Ru(benzene)Cl2/S-Sunphos/S-Daipen为催化剂,叔丁醇钾为碱,氢化温度60℃,氢化压力50atm,反应10小时,得类白色固体18.9g,收率99.4%。重结晶后得到白色固体,含量99.1%,de值99.1%。
实施例7:面膜
制剂配方:
配置方法:
A相:加入适量水于烧杯中,70℃条件下依次加入准确称量的黄原胶、甜菜碱、海藻糖、对羟基苯乙酮、柠檬酸、柠檬酸钠搅拌溶解,冷却至40℃加入透明质酸钠、羟丙基四氢吡喃三醇搅拌至溶解,灭菌后待用。
B相:加入适量去离子水于烧杯中,70℃条件下、依次加入准确称量的甘油、辛酸癸酸聚乙二醇甘油酯、尼泊金甲酯、1,2-戊二醇、香精,降温至40℃,灭菌后待用。
将B相缓慢加入到A相中,继续搅拌至溶液清亮、均一,即得基质面膜液,将膜布充分浸润在面膜液中,即得抗衰老面膜。
实施例8:面霜
制剂配方:
配置方法:
将水、甘油、丁二醇、丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物(增稠剂)、丙烯酸羟乙酯/丙烯酰二甲基牛黄酸钠共聚物、羟苯甲酯、EDTA二钠、透明质酸钠、黄原胶混合作为水相,搅拌加热至80~85℃,恒温20min;将聚二甲基硅氧烷、霍霍巴籽油混合作为油相,搅拌加热至80~85℃,恒温20min;将水相与油相充分混合,加入氨甲基丙醇,搅拌降温至45℃,加入1,2-己二醇、苯氧乙醇、乙基己基甘油、香精、羟丙基四氢吡喃三醇后,搅拌均匀,即得。
胶原蛋白表达量测定试验
1.1实验材料
1.1.1细胞系:人真皮成纤维细胞(HSF),来源于上海葵赛生物科技有限公司。
1.1.2培养液:含10%胎牛血清的DMEM培养基(Gibco,Lot:2275120)
1.1.3培养条件:5%二氧化碳,温度37℃,培养箱湿度为70%-80%
1.1.4试剂盒:人Ⅳ型胶原蛋白ELISA试剂盒:购自上海雅吉生物科技有限公司(货号:YS00439B);人Ⅶ型胶原蛋白ELISA试剂盒:购自科鹿(武汉)生物科技有限责任公司(货号:ELK3163)
1.1.5测试样品:实施例1-6制得不同de值的玻色因,以及按照Cavezza A.等,Synthesis of Pro-XylaneTM:A new biologically active C-glycoside in aqueousmedia,Bioorganic&Medicinal Chemistry Letters,2009,19(3):845-849中方法制得含量90%、de值92%的玻色因。测试样品配制:取样品10mg,加入5ml完全培养基,配成浓度为2mg/mL的待测液(0.2%,m/m)。空白对照(Control组):PBS。
1.2实验步骤
1.2.1细胞常规培养。制备密度为0.6~0.8×105个/mL的细胞悬液,将细胞悬液接种于96孔细胞培养板,每孔100μL,培养12h。
1.2.2取出细胞培养板,分别加入不同浓度的测试样品及空白对照溶液,补充培养基至200μL,培养箱孵育72h。
1.2.3收集上清液,10000r/min离心20min。取上清液,采用ELISA试剂盒分别测定Ⅳ、Ⅶ型胶原蛋白含量。
1.3数据分析
数据采用Graphpad进行T-Test分析,并以均值±标准差表示,如果p<0.01考虑差异具有统计学意义。
Ⅳ、Ⅶ型胶原蛋白相对含量:以Control组(空白对照)为100%,计算各组相对含量。
1.4实验结果
Ⅳ型、Ⅶ型胶原蛋白含量测试结果见下表和图3-4。
**:与空白对照组(Control组)相比,差异具有统计学意义(p<0.01)。
Claims (10)
1.一种玻色因,其特征是所述玻色因中C-β-D-吡喃木糖苷-2-羟基丙烷含量95%以上,并含有C-β-D-吡喃木糖苷-2-(S)-羟基丙烷和C-β-D-吡喃木糖苷-2-(R)-羟基丙烷,其中C-β-D-吡喃木糖苷-2-(S)-羟基丙烷过量且de值92%以上。
2.根据权利要求1所述的玻色因,其中所述de值92.5%以上。
3.根据权利要求1-2所述的玻色因,其中C-β-D-吡喃木糖苷-2-羟基丙烷含量为98.5%以上。
4.一种制备权利要求1-3所述的玻色因的方法,其特征在于包括C-β-D-吡喃木糖苷-2-丙酮在碱和手性催化剂存在下在溶剂中催化氢化还原生成C-β-D-吡喃木糖苷-2-(S)-羟基丙烷的步骤,其中所述的手性催化剂为双膦双胺钌催化剂。
5.根据权利要求4所述的方法,其中所述的催化剂中双膦配体是选自如下配体的S构型。
6.根据权利要求4-5所述的方法,其中所述的催化剂中双胺配体是如下配体的S构型。
7.根据权利要求4-6所述的方法,其中所述溶剂选自甲醇、乙醇、异丙醇、正丙醇、正丁醇、异丁醇、叔丁醇、乙二醇单甲醚、乙二醇单乙醚、乙二醇单丁醚或乙二醇单异丙醚。
8.根据权利要求4-7所述的方法,其中所述碱选自碳酸钾、碳酸钠、氢氧化钠、氢氧化钾、氢氧化锂、叔丁醇钾、叔丁醇钠、叔丁醇锂、甲醇钠或乙醇钠。
9.一种组合物,其特征在于含有权利要求1-4任一项所述玻色因作为生物活性物质和生理学上可接受的辅料。
10.权利要求1-4任一项所述的玻色因在制备化妆品中的应用;优选地,所述的化妆品用于抗衰老。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021115390382 | 2021-12-15 | ||
CN202111539038 | 2021-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117263898A true CN117263898A (zh) | 2023-12-22 |
Family
ID=86774847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211491049.2A Pending CN117263898A (zh) | 2021-12-15 | 2022-11-25 | 一种玻色因及其生产方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117263898A (zh) |
WO (1) | WO2023109877A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116947795B (zh) * | 2023-07-27 | 2024-04-09 | 天津泰普制药有限公司 | 一种s-羟丙基四氢吡喃三醇的连续合成方法 |
CN117050045B (zh) * | 2023-10-10 | 2023-12-22 | 长沙创新药物工业技术研究院有限公司 | 一种s构型羟丙基四氢吡喃三醇的合成方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113173900A (zh) * | 2021-04-09 | 2021-07-27 | 海南夸克科技有限公司 | 一种玻色因的合成方法 |
CN113735811B (zh) * | 2021-11-03 | 2022-02-08 | 深圳瑞德林生物技术有限公司 | 一种通过酰化保护再还原合成玻色因的方法 |
-
2022
- 2022-11-25 CN CN202211491049.2A patent/CN117263898A/zh active Pending
- 2022-12-15 WO PCT/CN2022/139155 patent/WO2023109877A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023109877A1 (zh) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN117263898A (zh) | 一种玻色因及其生产方法和用途 | |
US7358346B2 (en) | C-glycosides, uses thereof | |
CN114209679B (zh) | 3,5-二羟基-4-甲氧基苄醇的合成方法及其应用 | |
CN108218862A (zh) | α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用 | |
CN103214534A (zh) | 一种3’-脱氧腺苷的制备方法 | |
CN112645913B (zh) | 一种对联三苯类化合物及其制备方法和应用 | |
JP6436337B2 (ja) | エラスチン産生作用を呈するケルセチン誘導体及びその製造方法 | |
CN107163041B (zh) | 一种β-咔啉化合物及其合成方法和应用 | |
CN105778890B (zh) | 一种噻吩三联吡啶化合物双光子吸收材料及其制备方法 | |
CN101077852A (zh) | 参麦注射液的化学成分的制备及其在治疗心脑血管疾病中的应用 | |
CN113980098A (zh) | 一种九肽-1衍生物及其合成方法和用途 | |
CN103755578B (zh) | 一种赤式结构盐酸甲氧明的制备方法 | |
EP2604605B1 (en) | Theanine derivative, preparation method thereof, and use thereof for alleviating acne | |
JP6741965B2 (ja) | ケラチン増加作用を呈するデヒドロレチノール誘導体 | |
CN112679443B (zh) | 一种果糖嗪的制备方法及用途 | |
CN112079889A (zh) | 一种新化合物及其在护肤品中的用途 | |
CN115819488B (zh) | 一种24,31-氢化茯苓酸、制备方法及其应用 | |
EP4219451A1 (en) | Crystal form of pyridinylphenyl compound and preparation method therefor | |
KR102202236B1 (ko) | 지방세포 분화 촉진 효능을 갖는 코지산 설파이드 유도체 화합물 및 이를 함유하는 화장료 조성물 | |
CN111349230B (zh) | 一种含peg查尔酮衍生物前药和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用 | |
CN116712525B (zh) | 一种亮白美肌生物活性材料注射液及其制备方法 | |
CN116478118A (zh) | R-/s-羟丙基四氢吡喃三醇的合成方法 | |
CN114933558B (zh) | 手性硝基化合物催化还原制备手性氨基化合物的方法 | |
CN103073485A (zh) | 一种丁酸氯维地平的制备方法 | |
CN115340457A (zh) | 一种天然活性小分子化合物、组合物、提取物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |